The Life Sciences team advised SciAps in its acquisition by Spectris PLC for up to $260 million comprising up-front consideration of $200 million plus a deferred element of up to $60 million payable on the delivery of agreed financial metrics. The transaction is subject to customary completion conditions and regulatory approvals, with completion expected to take place later this year.
Based in Boston, Massachusetts, SciAps is a high-growth, specialist provider of handheld instruments leveraging X-ray Fluorescence (XRF) and Laser Induced Breakdown Spectroscopy (LIBS) techniques for materials analysis. Its strong culture of innovation and differentiated handheld technology has enabled it to develop a strong presence in its market over recent years and an attractive pipeline of new products.
The Goodwin team was led by Stuart Cable and Robert Dzialo and included Leilani Lipa, and Andrea Akinbola.
For additional details on the acquisition, please read the press release.